Hidayat K, et al. - Researchers conducted this systematic review and meta-analysis of observational studies to explore the connection between the risk of fracture and the use of metformin, insulin, sulphonylureas, or thiazolidinediones. Insulin, sulphonylureas, and thiazolidinediones use was correlated with an increased risk of fracture; metformin use was related to a reduced risk of fracture. Both pioglitazone and rosiglitazone have been positively linked to the risk of fracture. Overall, authors concluded that there is compelling proof to discourage the use of thiazolidinediones in people with an increased risk of fracture, while metformin seems to have a strong safety profile for fracture risk. The decreased general risk of fracture among consumers of metformin maybe the reason for the lower risk of fracture with metformin, as this medication is usually prescribed in the early stages of type 2 diabetes mellitus. The use of insulin or sulphonylureas may increase the risk of fracture, most likely due to an increased risk of falling due to hypoglycemia.